A recent symposium at the European Society of Intensive Care Medicine (ESICM) LIVES Congress in Munich addressed vasoplegia, a critical condition in intensive care units. Experts explored its pathophysiology, clinical identification, and management, highlighting Angiotensin II as a promising targeted therapy.
Jean-Louis Vincent explained that vasoplegia involves sustained low systemic vascular resistance and uncontrolled vasodilation, leading to hypotension. He emphasized the need for comprehensive hemodynamic assessment. The Renin-Angiotensin-Aldosterone System (RAAS) plays a crucial role, with Angiotensin II being a key vasoconstrictor. Studies like ATHOS-3 demonstrated Angiotensin II's effectiveness in increasing blood pressure in patients unresponsive to conventional vasopressors. Impaired Angiotensin II production in distributive shock is linked to higher mortality, making RAAS modulation a vital therapeutic consideration.
Gianluca Paternoster detailed clinical challenges, noting that refractory vasoplegic shock results from severe peripheral vasodilation and inadequate response to standard vasopressors. He described how RAAS imbalance, particularly AT1 receptor downregulation, reduces catecholamine sensitivity. Paternoster suggested a shift towards non-adrenergic approaches to rebalance the RAAS in these patients.
Ricard Ferrer presented evidence supporting Angiotensin II's use, citing preclinical models and the ATHOS-3 trial. The study showed significantly improved blood pressure response with Angiotensin II compared to placebo in patients with vasodilatory shock. Ferrer highlighted patient subgroups who may benefit most, including those with hyperreninemia, prior ACE inhibitor exposure, or acute kidney injury.
Emily See provided practical insights into applying Angiotensin II. She described its rapid titratability and administration protocols. See also discussed the AIMRITE tool for identifying responders and addressed safety considerations, noting that current data show no increased risk of thromboembolic events compared to placebo. Ongoing studies aim to further refine its use in specific patient populations.
The consensus points towards Angiotensin II as a valuable addition to the ICU's vasopressor toolkit, offering a targeted approach to managing complex vasoplegic shock cases.